ARA-290
Also known as: Cibinetide
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Pricing for ARA-290
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for ARA-290
27 third-party tests across 12 vendors. Each card links to the full report.
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
ARA-290
by Riptide Wellness· batch RWARA-10-1002
For
ARA-290
by Verified Peptides· batch ARA04260312C
For
ARA-290
by Peptide Supply Co.· batch AR1022026
For
ARA-290
by BioLongevity Labs· batch 2-3-46035
For
ARA-290
by Ion Peptide· batch ARA10-01212026
For
ARA-290
by BioLongevity Labs· batch cmojb6w60016nkirxxcy5khmm
For
ARA290
by Mile High Compounds· batch ARA-012-MH-01
For
ARA-290
by Skye Peptides· batch ARA25-16-004
For
ARA-290
by Ion Peptide· batch ARA16-12082025
For
ARA-290
by Ion Peptide· batch ARA-12125
For
ARA-290
by Ion Peptide· batch ARA10-1125
For
ARA-290
by Profound Aminos· batch cmojb843w01gpkirxqc44yi4i
For
ARA-290
by Verified Peptides· batch cmojb5loj00x0kirxueirm4wr
For
ARA-290
by Skye Peptides· batch ARA25-16-003
For
ARA-290
by Profound Aminos· batch 2025-04-03
For
ARA-290
by Verified Peptides· batch 01-25-0112A
For
ARA-290
by Peptide Tech· batch cmpac5e260003tmrxbc4tckd2
For
ARA-290
by BioLongevity Labs· batch cmojb7cp501akkirxbr8ea2wa
For
ARA-290
by Glacier Aminos· batch ARA16GA01
For
ARA-290
by Real Peptides· batch RP052226
Purity not on file
For
ARA-290
by Skye Peptides· batch ARA25-16-004
Purity not on file
For
ARA-290
by Skye Peptides· batch ARA25-16-004
16 citations indexed for ARA-290
animal · 2026
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.
review · 2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
A wound has been defined as a disruption of tissue integrity. Pain, bleeding, and the risk of infection are inherent features of wounds, while chronic wounds are often accompanied by serous exudate.
review · 2025
Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging
Cardiology is continually evolving towards increased personalization with targeted diagnostics and therapeutics.
review · 2025
Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders
Erythropoietin (EPO), a glycoprotein hormone primarily produced by the kidneys, is essential for erythropoiesis. Beyond its well-established hematopoietic function, EPO has emerged as a regulator of metabolic inflammation.
review · 2025
Effects of Peptides and Bioactive Peptides on Acute Kidney Injury: A Review Study
Acute kidney injury (AKI) is the sudden loss of kidney function that occurs within hours or days, resulting in the accumulation of waste materials in the blood and disruption of fluid balance. AKI is prevalent among hospitalized patients, especially the elderly in the intensive care units.
Study · 2023
Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways
ARA 290, an 11-amino acid linear nonhematopoietic peptide derived from the three-dimensional structure of helix B of the erythropoietin (EPO), interacts selectively with the innate repair receptor (IRR) that arbitrates tissue protection.